Breast Cancer Vaccine Study
Author Information
Author(s): Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, Livingston P
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
The study investigates the specificity of immune responses in breast cancer patients vaccinated with a MUC1 peptide conjugate.
Conclusion
The immune sera from breast cancer patients recognized a specific epitope but showed weak reactivity against MUC1-positive tumor cells.
Supporting Evidence
- The MUC1 protein is expressed differently in breast cancer compared to normal tissues.
- Patients produced high levels of antibodies against the MUC1 peptide after vaccination.
- Only the specific APDTRPA epitope was recognized by the immune sera.
Takeaway
Scientists gave a vaccine to six breast cancer patients to see how their bodies reacted, and they found that the patients' immune systems recognized a specific part of the cancer but didn't attack the cancer cells very well.
Methodology
The study involved immunizing breast cancer patients with a MUC1 peptide conjugate and analyzing the immune response through ELISA and inhibition assays.
Limitations
The study's findings may not be generalizable due to the small sample size.
Participant Demographics
Six breast cancer patients were involved in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website